Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers
Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...
Interested in a collaboration?
Contact us to discuss the possibilities.